

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders.

In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

(Translation)

May 20, 2024

To Shareholders,

Company Name: Renascience Inc.
Representative: Koji Naito, President & CEO
(Code: 4889 TSE Growth)
For inquiries, please contact Administration Dept.

**Notice of Termination of License Agreement with Baxter Healthcare
Corporation for Disposable Ultrafine Endoscope**

The Company today announces that it has terminated a license agreement with Baxter Helthcare Corporation (hereinafter referred to as "Baxter") of the United States for the disposable ultrafine endoscope (hereinafter referred to as "Device").

1. Background of Termination of the license agreement

In May 2020, the Company entered into a license agreement with Baxter for the co-development and commercialization of the Device that enables noninvasive peritoneal observation in peritoneal dialysis therapy. In December 2022, the Ministry of Health, Labour and Welfare (MHLW) approved the fiberscope, the main component of the Device, and Baxter planned to commercialize it. Baxter however decided to withdraw from the business, leading to the termination of the license agreement.

2. Impact on business performance of the Company

A termination fee of 20 million yen for the termination of the license agreement with Baxter will be recorded in the fiscal year ending March 31, 2025.

End